Improvement in psoriasis after intradermal administration of delipidated, deglycolipidated Mycobacterium vaccae (PVAC™): Results of an open-label trial

Clinical and Experimental Dermatology

Volumn 26, Issue 3, 2001, Pages 233-241

  Balagon, M V ^b   Tan, P L ^a   Prestidge, R ^a   Cellona, R V ^b   Abalos, R M ^b   Tan, E V ^b   Walsh, G P ^b   Watson, J D ^a   Walsh, D S ^c,d  

^a Genesis Research & Development Corporation Ltd   (New Zealand)

^b Leonard Wood Memorial Center for Leprosy Research Philippines   (Philippines)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^d APACHE POINT OBSERVATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; MYCOBACTERIUM VACCAE SUSPENSION; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; EXFOLIATIVE DERMATITIS; FEMALE; HUMAN; INOCULATION; MALE; MYCOBACTERIUM VACCAE; PRIORITY JOURNAL; PSORIASIS; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BACTERIAL VACCINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; MIDDLE AGED; MYCOBACTERIUM; PSORIASIS; SEVERITY OF ILLNESS INDEX; VACCINES, INACTIVATED;

EID: 0035725711     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2001.00804.x     Document Type: Article

References (25)

1. Recent advances in the treatment of psoriasis
2. Immunopathogenesis and immunotherapy of psoriasis
3. The pathogenesis of psoriasis: Immunological facts and speculations
4. Cyclosporine immunotherapy
5. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
6. Immunotherapy with Mycobacterium vaccae and the treatment of tuberculosis
7. Immunotherapy of tuberculosis with Mycobacterium vaccae NCTC 11659
8. Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis
9. A preliminary report on the immunotherapy of psoriasis
10. Improvement in psoriasis after intradermal administration of Mycobacterium vaccae
11. Severe psoriasis: Oral therapy with a new retinoid
12. Recombinant interleukin-2 in lepromatous leprosy lesions: Immunological and microbiological consequences
13. Epidemiology of disease caused by nontuberculous mycobacteria
14. Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae
15. Immunotherapy with Mycobacterium vaccae combined with second line chemotherapy in drug-resistant abdominal tuberculosis
16. Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis
17. Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis
18. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis, a randomised controlled trial
19. Whither Mycobacterium vaccae?
20. Mycobacterium vaccae: A study of safety and outcome measures
21. Immunization of healthy adult subjects in the United States with inactivated Mycobacterium vaccae administered in a three-dose series
22. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae
23. Immunization with heat-killed Mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis
24. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: A new therapeutic approach
25. The immunopathology of psoriasis